WELCOME IRAP International Symposium 2024

“The cautionary tale of three inhibitors”

​

Efstratios Stratikos is an Associate Professor of Biochemistry and the Director of the Laboratory of Biochemistry of the Department of Chemistry at the National and Kapodistrian University of Athens, Greece. He is also an Adjunct Researcher at the National Centre for Scientific Research “Demokritos”. After obtaining a degree in Chemistry from the University of Athens in 1994, he continued his studies in the USA, at the University of Illinois Medical School in Chicago, where he obtained a PhD in Biochemistry in 1999. From 1999 to 2004 he was a postdoctoral researcher at Harvard University in Boston, USA. From 2005 to 2020 he worked as a researcher at the National Centre for Scientific Research "Demokritos" where he was promoted to the rank of Research Director in 2014 as head of the Protein Chemistry Laboratory. Since 2020 he has been working at the National and Kapodistrian University of Athens. His research interests focus on the study of proteins and their role in human disease and in particular on the molecular mechanisms of the human immune system.

​

Personal web page: http://users.uoa.gr/~estratikos/

​

Lab web page: https://biochemistry.chem.uoa.gr/

"Anti-fibrotic drugs in clinical practice"

​

Prof Louise Burrell is an active clinician-researcher with specialty training in Endocrinology and Internal Medicine and a significant track record of translational research in cardiovascular disease and related conditions. She is a Professor of Medicine at the University of Melbourne, Head of the Cardiovascular Research Group, and an Honorary Professor of Medicine at Dundee University. Her research program investigates the pathophysiology and treatment of cardiovascular disease with work that spans laboratory science and clinical research. She is internationally known for contributions and leadership in regard to the understanding and management of cardiovascular disease, particularly as it relates to the renin angiotensin system.  She has a particular interest in role of ACE2 as a biomarker of risk in heart and kidney disease. She also has significant experience in randomised clinical trials, and recently led a large trial that studied the effect of climate on hospital admissions, and was involved in another that repurposed of existing medications to reduce severe acute respiratory distress in patients with COVID-19.